2025年晚餐短期課程* （僅限面對面實體會議）

Drug Discovery Chemistry的短期課程旨在具有指導性、互動性，並提供關於特定主題的深入資訊，以及貫穿始終的問答機會。這些課程為剛接觸這個領域的新手及希望了解更多資訊的人闡述說明在主體會議的簡報單元囚於時間限制而不及深入的抜術面入門知識。講師來自業界和學術界，其中多數是該領域公認的權威或具有教學經驗的指導者。

短期晚餐課程將於 4 月 14 日星期一和 4 月 16 日星期三晚上舉行，對現場與會者開放。

*需要較高價報名費或單獨報名

2025年4月14日（星期一）下午 6:00 - 8:30

SC1: Protein Degraders: A Beyond Rule of Five Space and in vitro ADME Perspective

Detailed Agenda

This course focuses on proteolysis targeting chimeras (PROTACs) and will cover topics relevant to developing them as oral therapeutics. Topics to be covered in this part of the course will include their physicochemical properties and how these influence solubility and permeability and assays to determine polarity. We will also examine ADME topics focusing on in vitro assays including stability assays, transporters, drug-drug interactions (DDIs), Cytochrome P450 (CYP450) inhibition, etc.

John Erve, PhD, President, Jerve Scientific Consulting

Stefanus Steyn, PhD, Research Fellow, Pharmacokinetics Dynamics & Metabolism, Pfizer

Instructors:

John Erve, PhD, President, Jerve Scientific Consulting

Stefanus Steyn, PhD, Research Fellow, Pharmacokinetics Dynamics & Metabolism, Pfizer

Topics to be Covered:

Comparison of Rule of Five and Beyond Rule of Five space
Importance of intramolecular hydrogen bonds for solubility and permeability
Determining chameleonicity and its importance for PROTACs
Transporters and potential drug-drug interactions (DDIs)

Who Should Attend:

Scientists in the field of proteolysis-targeting chimeras (PROTACs) who would like to deepen their understanding of these molecules and the physicochemical attributes that may contribute to their success as oral drugs. ADME scientists and medicinal chemists wishing to understand PROTACs from a drug safety and metabolism perspective. Graduate students and academic scientists interested in learning more about this rapidly developing new drug modality.

INSTRUCTOR BIOGRAPHIES:

John Erve, PhD, President, Jerve Scientific Consulting

John Erve is from Chicago and studied Chemistry (BS, MS) at the University of Chicago and earned a PhD in Toxicology at Oregon State University. Following postdoctoral work at Vanderbilt (1995-1999) he joined BD-Biosciences (Woburn, MA) as a Study Director. In 2002, he joined AstraZeneca (Sweden) where he characterized reactive metabolites. In 2004 he joined Wyeth (Collegeville, PA) as a Principal Scientist responsible for metabolite identification. In 2010, John joined Novartis (Cambridge, MA) as a Lab Head in Analytical Sciences. John returned to drug metabolism at Elan Pharmaceuticals (San Francisco, CA) in 2012 and later formed Jerve Scientific Consulting, Inc to help small biotech companies in the Bay area with their drug discovery efforts. John was a certified D.A.B.T. from 2004 to 2019.

Stefanus Steyn, PhD, Research Fellow, Pharmacokinetics Dynamics & Metabolism, Pfizer

I have a Ph.D. in Pharmaceutical Chemistry and completed post-doctoral studies in the laboratory of Professor Neal Castagnoli at Virginia Tech. I have over 20 years pharmaceutical industry experience with over forty co-authored publications. I have spent most of my career at Pfizer in various roles within PDM (DMPK), supporting projects ranging from oncology to neuroscience and currently, Inflammation and Immunology (I&I). I am currently a Research Fellow, and my responsibilities include setting the DMPK research and project strategies within the I&I Research Unit. In addition, my team and I function as Project Representative within I&I while I also have responsibilities as a Research Project Lead for various Discovery programs. My interests include prediction of human ADME as well as exploring physicochemical properties and how they relate to ADME with a focus on absorption. PROTACs are of special interest given their unique beyond Rule-of-5 properties and the ADME challenges they present relative to classical small molecules.

SC2: Fragment-Based Drug Design: Advancing Tools and Technologies

Detailed Agenda

This course aims to introduce the fundamentals of Fragment-Based Lead Discovery (FBLD) to attendees. The first section will focus on the concepts of using fragments for hit generation. Special emphasis will be placed on practical pitfalls and the many ways to advance fragments to leads and drugs. The second part of the course will discuss the variety of fragment screening methods and when they are best applied. The composition of fragment libraries will also be discussed in detail. The attendees should come away from this course with a solid understanding of what FBLD is and how to apply it.

Ben J. Davis, PhD, Research Fellow, Biology, Vernalis R&D Ltd.

Daniel A. Erlanson, PhD, Chief Innovation Officer, Innovation and Discovery, Frontier Medicines Corporation

Instructors:

Ben J. Davis, PhD, Research Fellow, Biology, Vernalis R&D Ltd.

Daniel A. Erlanson, PhD, Chief Innovation Officer, Innovation and Discovery, Frontier Medicines Corporation

Topics to be Covered:

Pros and cons of fragment-based approaches
What makes a good fragment; properties of a good fragment library
Finding, validating, and characterizing low-affinity ligands
The importance of using orthogonal screening methods
What to do with a fragment—growing, linking, and more

INSTRUCTOR BIOGRAPHIES:

Ben J. Davis, PhD, Research Fellow, Biology, Vernalis R&D Ltd.

Dr. Ben Davis is a Research Fellow at Vernalis Research, a biotech company based in Cambridge UK which has been at the forefront of fragment-based approaches since 1998. An NMR spectroscopist and biophysicist by training, his current research focus is the development of biophysics and FBLD methods for challenging therapeutic targets and systems. Dr Davis studied for his PhD in protein folding and molecular interactions with Professor Alan Fersht at Cambridge University, and then studied the interactions of small molecules with proteins and RNA. He has over 20 years’ experience in the drug discovery industry. He has contributed to seven books over the last decade and is an author on more than forty scientific publications. He is a frequent speaker at scientific conferences and has been running FBLD training workshops since 2007.

Daniel A. Erlanson, PhD, Chief Innovation Officer, Innovation and Discovery, Frontier Medicines Corporation

Dr. Daniel A. Erlanson is the Chief Innovation Officer for Frontier Medicines, which is using covalent fragments, machine learning, and chemoproteomics to target proteins often thought undruggable. Prior to Frontier he co-founded Carmot Therapeutics, where he contributed to two clinical-stage molecules. Before Carmot, Dr. Erlanson spent a decade developing fragment-based discovery technologies and leading medicinal chemistry projects at Sunesis Pharmaceuticals. Dr. Erlanson was an NIH postdoctoral fellow with James A. Wells at Genentech, earned his PhD in chemistry from Harvard University in the laboratory of Gregory L. Verdine, and his BA in chemistry from Carleton College. He has co-edited two books on fragment-based drug discovery and is an inventor on more than a dozen issued patents and an author of more than forty scientific publications. He also runs a blog devoted to fragment-based drug discovery, Practical Fragments (http://practicalfragments.blogspot.com/).

SC3: Fundamentals of Generative AI for Drug Discovery

Detailed Agenda

Deep generative modeling is rapidly transforming de novo drug discovery, streamlining the entire process. This course aims to explain the potential of AI, machine learning, and generative AI models in creating tailored molecules with specific properties. It explores the fundamentals of Variational Autoencoders, Generative Adversarial Networks, Transformers, Large Language Models (LLMs), BERT, and GPT models in the context of drug discovery, highlighting their crucial role in reshaping the pharmaceutical landscape. Along the way, we'll dissect three pivotal techniques for biopharma specific LLMs: prompt engineering, retrieval augmented generation (RAG), and fine-tuning. This course is designed for medicinal chemists, molecular modeling users, and project managers seeking to harness the capabilities of modern Generative AI concepts and integrate them into their work.

Parthiban Srinivasan, PhD, Professor and Director, Centre for AI in Medicine, Vinayaka Mission's Research Foundation, India

Petrina Kamya, PhD, Global Head of AI Platforms & Vice President, Insilico Medicine; President, Insilico Medicine Canada

Instructors:

Parthiban Srinivasan, PhD, Professor and Director, Centre for AI in Medicine, Vinayaka Mission's Research Foundation, India

Petrina Kamya, PhD, Global Head of AI Platforms & Vice President, Insilico Medicine; President, Insilico Medicine Canada

Topics to be Covered:

Demystifying generative AI concepts and key terminologies
How predictive and generative AI works in de novo molecular design
Overview of large language models (LLMs)
Prompt engineering, RAG, and fine-tuning for biopharma-specific LLMs
Leveraging language models in drug discovery research with case studies

Who Should Attend:

This course is designed for medicinal chemists, molecular modeling users, and project managers seeking to harness the capabilities of modern generative AI concepts and integrate them into their work.

INSTRUCTOR BIOGRAPHIES:

Parthiban Srinivasan, PhD, Professor and Director, Centre for AI in Medicine, Vinayaka Mission's Research Foundation, India

Parthiban Srinivasan, an experienced data scientist, earned his PhD from Indian Institute of Science, specializing in Computational Chemistry. After his PhD, he continued the research at NASA Ames Research Center (USA) and Weizmann Institute of Science (Israel). Then he worked at AstraZeneca in the area of Computer Aided Drug Design for Tuberculosis. Later, he headed informatics business units in Jubilant Biosys and then in GvkBio before he floated the company, Parthys Reverse Informatics and later an AI consultancy, Vingyani. Then he returned to academia as a Professor of Data Science at the Indian Institute of Science Education and Research, Bhopal. Currently, Parthiban is a Professor and Director at the Center for AI in Medicine, Vinayaka Missions Research Foundation, AV Medical College and Hospital, Puducherry, India

Petrina Kamya, PhD, Global Head of AI Platforms & Vice President, Insilico Medicine; President, Insilico Medicine Canada

Petrina Kamya, PhD, is the Head of AI Platforms and President of Insilico Medicine, Canada an end-to-end artificial intelligence-driven drug discovery company. Before joining Insilico, Dr. Kamya spent eight years in various roles at Chemical Computing Group that involved scientific and business-related aspects of preclinical drug discovery. In addition to establishing the corporate strategy for the sales and business development of molecular modeling software for academia, she also played an active role as an application scientist working on real-world discovery projects and finally in a senior role in strategy and business development for pharma and biotech companies. Following her time at CCG, Petrina moved to Certara as a Market Access Manager, where she learned first-hand the challenges of getting drugs to market. Petrina has been with Insilico Medicine since August 2020. She holds a PhD in Chemistry (specializing in computational chemistry) from Concordia University.

SC4: Detecting Target Engagement: Technology Innovations

Detailed Agenda

This course covers a range of biochemical or biophysical tools adapted to gauge interaction between a compound of interest (either a tool compound or potential therapeutic) with its intended disease-related molecular target. Most of the applications are employed at the hit-confirmation steps in the drug lead generation process, to discover small molecule compounds that engage difficult-to-drug protein targets. Applications to primary screening steps may also be covered.

Hans-Peter N. Biemann, PhD, Distinguished Scientist, Integrated Drug Discovery, Sanofi

Jonathan Brooks, Principal Scientist, Inflammation & Remodeling, Pfizer Inc.

Elmar Nurmemmedov, PhD, MBA, Co-Founder & CEO, CellarisBio

Instructors:

Hans-Peter N. Biemann, PhD, Distinguished Scientist, Integrated Drug Discovery, Sanofi

Jonathan Brooks, Principal Scientist, Inflammation & Remodeling, Pfizer Inc.

Elmar Nurmemmedov, PhD, MBA, Co-Founder & CEO, CellarisBio

Topics to be Covered:

Fluorescence Resonance Energy Transfer (FRET)-based Applications for Cellular Target Engagement: by Elmar Nurmemmedov, CellarisBio
Affinity Selection Mass Spectrometry (ASMS): by Hans Biemman, Sanofi
SPR microscopy: by Jonathan Brooks, Pfizer

INSTRUCTOR BIOGRAPHIES:

Hans-Peter N. Biemann, PhD, Distinguished Scientist, Integrated Drug Discovery, Sanofi

Hans-Peter Biemann has originated innovative discovery programs and applied emerging small molecule technologies during tenures in Genzyme’s and Sanofi’s Drug Discovery units. Contributions on preclinical and clinical agents have included partnerships with academic leaders and start-ups. Working across various disciplines (protein biochemistry, cell biology, structural biology, biophysics), Hans has conducted and led phenotypic, fragment-based, and HTS-based drug discovery. He established productive FBDD, high-res Cryo EM drug design, Affinity Selection Mass Spectrometry over the past 15 years at Sanofi/Genzyme. Prior to joining Genzyme in the 1990s, he completed a post doc in Daniel Koshland’s U.C. Berkeley group and trained in Raymond Erikson’s Harvard group (PhD). His B.S. was earned at Yale.

Jonathan Brooks, Principal Scientist, Inflammation & Remodeling, Pfizer Inc.

Jonathan began his career at Genetics Institute in 1990 developing immunoassays for use in pharmacokinetics and process development. Jon has over 30 years of experience in label free analysis of receptor ligand interactions and small molecule target binding associated with several respiratory and inflammatory disease areas. Currently, he is a principal scientist in the inflammation and Immunology drug discovery research unit at Pfizer in Cambridge Massachusetts. His current focus is on-cell target interaction analysis using SPRm. Jon received his MS in Biology from Harvard University.

Elmar Nurmemmedov, PhD, MBA, Co-Founder & CEO, CellarisBio

Elmar Nurmemmedov is a scientist in the field of drug discovery. PhD in molecular biophysics from Lund University, Sweden. Postdoctoral training from Harvard Medical School and Scripps Research Institute. Cofounder and CEO of CellarisBio.

2025年4月16日（星期三）下午 6:15 - 8:45

SC5: Protein Degraders: An in vivo ADME and Safety Perspective

Detailed Agenda

This course focuses on proteolysis targeting chimeras (PROTACs) and will cover topics relevant to developing them as therapeutics. Topics to be covered in this part of the course will include looking at what is known about how PROTACs are metabolized in vivo and strategies to deliver them with adequate PK/PD. The unique mechanism of action of PROTACs gives rise to some drug safety issues not seen in small molecules, which will be discussed. Finally, we will explore the possible relevance of circadian rhythm to protein degradation and PROTACs.

Donglu Zhang, PhD, Senior Fellow, DMPK, Genentech Inc.

John Erve, PhD, President, Jerve Scientific Consulting

Instructors:

Donglu Zhang, PhD, Senior Fellow, DMPK, Genentech Inc.

John Erve, PhD, President, Jerve Scientific Consulting

Topics to be Covered:

Measuring ADME properties in vitro and in vivo and specific challenges
Metabolism of PROTACs and influence of linker length on stability
Case study of optimizing a PROTAC
Safety issues unique to PROTACs
Circadian rhythm considerations

Who Should Attend:

Scientists in the field of proteolysis targeting chimeras (PROTACs) and would like to deepen their understanding of these molecules and the physicochemical attributes that may contribute to their success as oral drugs. ADME scientists and medicinal chemists wishing to understand PROTACs from a drug safety and metabolism perspective. Graduate students and academic scientists interested in learning more about this rapidly developing new drug modality.

INSTRUCTOR BIOGRAPHIES:

Donglu Zhang, PhD, Senior Fellow, DMPK, Genentech Inc.

Donglu Zhang is a Senior Fellow in DMPK at Genentech. He is interested in applying drug metabolism studies in drug design and development of both small molecule, protein degraders, and antibody-drug conjugates (ADC) drugs. He has done numerous human mass balance studies, investigated pharmacokinetic drivers for efficacy of modalities, designed drug delivery approaches, and involved in IND, NDA/BLA submissions. He received the Sir James Black Award for discovery of and original research on Eliquis from British Pharmacological Society (2018), and the Ondetti and Cushman Award for invention of mass defect filtering method (MDF) from Bristol-Myers Squibb (2007). He has co-authored 130 peer-reviewed articles. He received his Ph.D. in Organic Chemistry from University of Utah.

John Erve, PhD, President, Jerve Scientific Consulting

SC6: Chemical Biology for Covalent Drug Discovery, Phenotypic Screening, and Target Deconvolution

Detailed Agenda

This course is designed to provide an overview and best practices in the use of chemical biology probes and assays that have been developed for applications in early drug discovery. Chemists and biologists working in lead generation, assay development, phenotypic screening, target discovery and deconvolution, target engagement and mechanism-of-action (MoA) studies will all benefit from attending this course. The instructors will share their knowledge and expertise around the use of various technologies and chemistries, and there will be time for open discussion and exchange of ideas.

Paul Brennan, PhD, Professor, Nuffield Department of Medicine, University of Oxford

Brent Martin, PhD, Senior Director, Chemical Biology, Odyssey Therapeutics

Angelo Andres, Senior Scientist, Chemical Biology, AstraZeneca Pharmaceuticals

Instructors:

Paul Brennan, PhD, Professor, Nuffield Department of Medicine, University of Oxford

Brent Martin, PhD, Senior Director, Chemical Biology, Odyssey Therapeutics

Angelo Andres, Senior Scientist, Chemical Biology, AstraZeneca Pharmaceuticals

Topics to be Covered:

Chemical biology assays and probes for target engagement and mechanistic understanding
Chemoproteomic methods and reagents for covalent ligand drug discovery
Comparison of various chemical biology approaches (mass spectrometry, affinity-bead methods, proximity labeling proteomics, and more)
Use of quantitative mass spectrometry-based proteomics and global proteomics
Discovery of chemical probes
Constructing annotated chemogenomic compound sets for phenotypic screening
Cysteine profiling and covalent inhibitors for target discovery and occupancy
Design and screening of chemogenomics libraries for target identification
Case studies highlighting use of proteomics for target engagement and deconvolution

INSTRUCTOR BIOGRAPHIES:

Paul Brennan, PhD, Professor, Nuffield Department of Medicine, University of Oxford

Paul Brennan received his PhD in organic chemistry from UC Berkeley. Following post-doctoral research at Cambridge University, Paul spent eight years working in the pharmaceutical industry at Amgen and Pfizer. After leaving Pfizer in 2011, Paul joined the Structural Genomics Consortium at the University of Oxford and led the chemical probes discovery effort on epigenetic targets. After leaving the SGC in 2019, Paul was Head of Chemistry and then Chief Scientific Officer of the Alzheimer’s Research UK Oxford Drug Discovery Institute where his research was focused on finding new treatments for dementia. In addition to dementia, over the course of his career, Paul has worked on discovering new medicines for cancer, incontinence, pain, rare diseases, and inflammation. Paul is currently Professor of Medicinal Chemistry and Director of the Centre for Medicines Discovery at the University of Oxford and a scientific advisor to the biotech and pharmaceutical industries. His research centre is focused on early medicines discovery for poorly treated diseases.

Brent Martin, PhD, Senior Director, Chemical Biology, Odyssey Therapeutics

Brent Martin received his Ph.D. in Pharmacology at the University of California in San Diego developing new chemical strategies for correlated fluorescence and electron microscopy. He then carried out postdoctoral studies at the Scripps Research Institute developing new strategies for activity-based profiling, high-throughput screening, and chemical proteomics. As faculty member at the University of Michigan in Ann Arbor, he continued expanding the scope of activity-based profiling methods, while also establishing new bioconjugation reactions to detect and profile protein lipidation, redox modifications, and cysteine occupancy. Brent is the recipient of the NCI Howard Temin K99/R00 award in Cancer Research, the NIH Director’s New Innovator Award, and the NIGMS MIRA Established Investigator Award. He then moved to industry to lead the Chemical Biology at Janssen and was Vice President and Head of Chemical Biology at Scorpion Therapeutics.

Angelo Andres, Senior Scientist, Chemical Biology, AstraZeneca Pharmaceuticals

Angelo Andres is a Senior Scientist within the Chemical Biology & Proteomics group at AstraZeneca. Before embarking on his scientific journey he served in the GWOT with the U.S. Army. He then earned a PhD in Medicinal Chemistry from The University of Kansas where he specialized in the development of cellular probes and assays to study live cell target engagement by small molecules. At AstraZeneca he collaborates across functions to develop lysosomal degradation modalities, generate synthetic probes to facilitate lead generation, and applies proteomics to support drug discovery programs across multiple therapeutic modalities spanning small molecules, degraders, and cell therapies.

SC7: AI Applications in Drug Development: Strategies for Innovation and Integration

Detailed Agenda

This course is intended to facilitate harnessing the transformative potential of artificial intelligence (AI) in pharmaceutical R&D. Through engagement with real-world case studies, we intend to collaboratively gain insights into state-of-the-art technologies and develop strategies to effectively integrate AI into pharma R&D processes. This course is intended to equip the attendee with the knowledge to optimize their R&D pipeline, enhance strategic decision-making, and position their organization at the forefront of AI-driven innovation in pharmaceuticals.

Arvind Rao, PhD, Associate Professor, Department of Computational Medicine and Bioinformatics, University of Michigan

Instructor:

Arvind Rao, PhD, Associate Professor, Department of Computational Medicine and Bioinformatics, University of Michigan

Topics to be Covered:

AI applications in target discovery and predictive diagnostics
Machine learning strategies for patient stratification and personalized medicine
Frameworks for scaling AI initiatives across pharmaceutical organizations
Critical considerations for implementing and managing AI projects
Ethical implications and emerging trends in AI-driven drug development

Who Should Attend:

Designed for scientific directors, business development executives, and project managers, this program provides advanced insights and practical knowledge to drive innovation and foster effective collaboration between AI specialists and traditional R&D teams.

INSTRUCTOR BIOGRAPHIES:

Arvind Rao, PhD, Associate Professor, Department of Computational Medicine and Bioinformatics, University of Michigan

Arvind Rao is an Associate Professor in the Department of Computational Medicine and Bioinformatics at the University of Michigan. His group uses image analysis and machine learning methods to link image-derived phenotypes with genetic data, across biological scale (i.e. single cell, tissue and radiology data). Such methods have found application in radiogenomics and drug repurposing based on phenotypic screens. Arvind received his PhD in Electrical Engineering and Bioinformatics from the University of Michigan, specializing in transcriptional genomics, and was a Lane Postdoctoral Fellow at Carnegie Mellon University, specializing in bioimage informatics.

SC8: Principles of Drug Design: Ligand-Receptor Interactions and More

Detailed Agenda

This course provides an overview of protein-ligand interactions and drug design principles. The presentation is targeted to medicinal chemists. The course starts by covering hydrophobic, H-bonding and electrostatic interactions. Then the course moves into coverage of specialized topics such as conformation analysis, pi-stack, cation-pi, halogen bonding, protein-protein interface, and covalent inhibition. Medicinal chemistry case studies are incorporated.

Maricel Torrent, PhD, Principal Research Scientist, Computational Drug Discovery, AbbVie, Inc.

Instructor:

Maricel Torrent, PhD, Principal Research Scientist, Computational Drug Discovery, AbbVie, Inc.

Topics to be Covered:

Medicinal chemistry and structure-based drug design principles
Interpretation of atomic-level protein X-ray and modeled structures of binding mode
Understanding the relative amounts of potency gain from different types of interactions
Case studies to illustrate all the design strategies

INSTRUCTOR BIOGRAPHIES:

Maricel Torrent, PhD, Principal Research Scientist, Computational Drug Discovery, AbbVie, Inc.

Result-oriented Computational Chemist with more than two decades of pharma industry experience in the application of Molecular Modeling to small molecule drug discovery. Key player in global pharmaceutical companies, Merck, Abbott, AbbVie. Technical skills and scientific strengths include 3D- and 2D-, ligand-based and structure-based drug design, as well as data mining and analysis. Strong competence as a team player, team builder, mentor, and group leader. Excels at creatively solving challenging problems that require tenacity and drive, and that involve multiple experts. Co-author of more than 80 peer-reviewed scientific articles and patents; two book chapters.

SC9: DNA-Encoded Libraries

Detailed Agenda

This course provides an overview of DNA-Encoded Library (DEL) screening platforms, discusses common selection strategies for identifying novel hits from DEL campaigns and delves into parameters for building a library collection. The instructors will also cover strategic considerations in using DEL selection data to accelerate hit-to-lead steps in drug discovery.

Svetlana Belyanskaya, PhD, Co-Founder, DEL Source; former Vice President, Biology, Anagenex

Ghotas Evindar, PhD, Co-Founder & President, DEL Source; former DEL Platform Senior Manager and Group Leader, GSK

Instructors:

Svetlana Belyanskaya, PhD, Co-Founder, DEL Source; former Vice President, Biology, Anagenex

Ghotas Evindar, PhD, Co-Founder & President, DEL Source; former DEL Platform Senior Manager and Group Leader, GSK

Topics to be Covered:

Introduction to DNA-encoded libraries
Pros and cons of using DNA-encoded chemical libraries
Structure of the DNA coding region and how it has evolved over time
Affinity-based selection strategy and how it guides hit-picking
Data analysis and the decision-making logic in hit confirmation
Introduction to and benefits of one-bead, one-compound (OBOC) DNA-encoded libraries

INSTRUCTOR BIOGRAPHIES:

Svetlana Belyanskaya, PhD, Co-Founder, DEL Source; former Vice President, Biology, Anagenex

Dr. Belyanskaya is an accomplished scientific leader in the field of small molecule drug discovery and an expert in DNA encoded library technology. She has been an instrumental player in the discovery of the first DEL-sourced molecule to progress into clinical trials. For more than 20 years she has been working in the DEL field and has made a significant contribution to the development of this platform at Praecis Pharmaceuticals, GlaxoSmithKline, Anagenex Inc. She is passionate about DEL platform development and constantly publicizing this technology at scientific conferences and seminars. She has multiple publications in the field of DEL technology, has taught short courses on DEL, and works as a consultant for startup companies. Dr. Belyanskaya held senior positions in the leading cross-functional team at GSK and has served as a Vice President of Biology at Anagenex Inc. Currently, she is a co-founder and a member of the executive team at DEL Source Inc. (LinkedIn).

Ghotas Evindar, PhD, Co-Founder & President, DEL Source; former DEL Platform Senior Manager and Group Leader, GSK

Dr. Evindar is co-founder and president of DEL Source Inc and a sought-after drug discovery advisor and consultant throughout the biotech and pharma industry. Born and raised in the Kurdish mountains and educated in Canada, he earned his bachelor’s and master’s degrees from the University of Waterloo, in biochemistry and bio-organic chemistry, respectively, and a PhD degree in organic chemistry from the University of Toronto. He initiated his industrial career as a medicinal chemist at Vertex Pharmaceuticals (Boston) with focus on structure-based drug design. Dr. Evindar led the DNA Encoded Library (DEL) platform discovery group at GSK and was a senior site manager and group leader at GSK Boston for 15 years. Prior to DEL Source, Dr. Evindar was an executive team member and head of drug discovery at both 1859 Inc and Exo Therapeutics. He is an expert in drug discovery and one of the pioneers of DEL platform, working in the original team enabling the platform from its early days at Praecis Pharmaceuticals. Over the last 20 years, Dr. Evindar led a number of medicinal chemistry programs and been involved with advancing a dozen molecules from early discovery to development stage. He has been a tireless advocate of DEL platform, serving as an advisor throughout the industry and as an educational leader through presentations, roundtables, and DEL courses to support DEL implementation and its application in drug discovery. He has authored well over 50 publications and patents in the fields of screening and drug discovery, including seminal articles on DNA-Encoded Library (DEL) technology (LinkedIn).

* 活動內容有可能不事先告知作更動及調整。

Choose your language